|
|
|
 |
|
製品情報 - Active Pharma Ingredients(API) - Antineoplastic Agents
|
Dasatinib(BMS-354825)
| カタログ : |
C13540 |
| 製品の名前: |
Dasatinib(BMS-354825) |
| 同義語: |
BMS 354825;Sprycel |
| 化学の名前: |
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide |
| CASナンバー : |
302962-49-8 |
| 構成 : |
|
| 分子式: |
C22H26ClN7O2S |
| 分子量: |
488.01 |
| 溶解度: |
Soluble in DMSO (200 mg/mL),very poorly soluble in ethanol and water |
| 純度: |
>99% |
| 使い方: |
Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib is a potent wild-type and mutant c-Abl inhibitor, except T315I. Dasatinib directly targets wild-type and mutant c-Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. Dasatinib treatment inhibits SRC signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. |
|
| 制品、有效に関する特許保護を売却せず、国家、売却こうした製品の特許侵害金人で、それは私たちの知らない特許の情况は全ての国、特許侵害責任は、十分に理解できるをバイヤーのリスクを高める. |
|
|
